EDIT Stock Recent News

The average of price targets set by Wall Street analysts indicates a potential upside of 80% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)

Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:

Editas Medicine's shares could skyrocket as it advances its gene-editing therapies. Recursion Pharmaceuticals is looking to implement a paradigm shift in drug discovery.

Editas Medicine is a gene-editing biotech, just like CRISPR Therapeutics. Editas has a long way to go before it'll be self-sustaining, and it might not get there.

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.

Editas Medicine is a clinical-stage drugmaker developing CRISPR-based gene therapies. So far, Editas Medicine's candidate for sickle cell disease patients is performing well in clinical trials.

Editas Medicine, Inc. (EDIT) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)